NCT03383406 - A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG

Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy

"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1\~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1\~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1\~Day3 by Intravenous infusion."